IE^SJPsJ/\ ESTABLISHED INNOVATIONS IN DIAGNOSTICS PGX-HIV StripAssayTest for genetic markers that influence highly active antiretroviral therapy (HAART) in HIV-positive patients PGX-HIV Assay. Key to efficient therapy. Highly active antiviral therapy (HAART), the combined use of different types of antiretroviral drugs, can efficiently combat AIDS. HAART works most effectively, and side effects can be minimized when genetic variations of the individual patient are taken into account. Genetic parameters of the individual patient contribute to differences in the response to HAART. Such factors affect the uptake or inactivation of HAART components and include allelic variants of the multidrug transporter P-glycoprotein 1 (MDR1), cytochrome P450 isozyme 2D6 (CYP2D6) and the C-C chemokine receptor 5 (CCR5). ViennaLab's PGX-HIV StripAssay® offers an easy way to identify the most relevant genetic variations influencing highly active antiretroviral therapy (HAART).

ESTABLISHED INNOVATIONS IN DIAGNOSTICS The ViennaLab PGX-HIV StripAssay® meets customer requirementsRequirement ViennaLab’s offer Easy Three simple steps. 6 h. Done. Reliable Probes for variants and controls combined on one teststrip. Versatile Automated or manual processing. Incubator.Thermocycler. Shaker. That is all you need. Software for interpretation of results is optional. • is based on reverse-hybridization of biotinylated MDR1 (3435 C>T), CYP2D6 (*3/*4/*6) PCR products and CCR5 (32 bp deletion) • combines probes for variants and controls in a parallel array of allele-specific oligonucleotides...